MetaVia Phase 2a DA-1241 hits ALT reduction of 22.8 U/L, CAP score down 23 dB/m in MASH patients

MetaVia Inc.

DA-1241 100 mg lowered ALT by 22.8 U/L (p<0.05 vs placebo) after 16 weeks in patients with baseline ALT 40-200 U/L.
Liver fat (CAP) reduced 23.0 dB/m with DA-1241 100 mg vs 1.4 dB/m placebo; FAST score dropped from 0.559 to 0.371.
HbA1c decreased 0.54%p at week 16 (baseline 6.99%); in type 2 diabetes subgroup, HbA1c fell 1.08%p.
Inflammation and fibrosis biomarkers (hs-CRP, CCL2, TIMP1) improved significantly (p<0.05 vs placebo).
Well tolerated; no TEAEs leading to discontinuation except one placebo; company plans end-of-Phase 2 FDA meeting H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.